Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15162786 | 0.91 | LTA4H (0.42) | LTA4HBCHEACHECA2CA1 | |
| SCHEMBL15162785 | 0.91 | LTA4H (0.42) | LTA4HBCHEACHECA2CA1 | |
| SCHEMBL12426453 | 0.89 | ALDH1A1 (0.39) | LTA4HBCHEACHEPPARG | |
| SCHEMBL12509869 | 0.86 | LTA4H (0.36) | LTA4HBCHEACHEPPARGPPARA | |
| SCHEMBL12426467 | 0.85 | ALDH1A1 (0.43) | CA2PPARGCA1SMN1; SMN2 | |
| SCHEMBL12426460 | 0.85 | BCHE (0.37) | BCHEPPARGPPARARORC | |
| SCHEMBL12426475 | 0.84 | BCHE (0.39) | BCHEACHECA2CA1RORC | |
| SCHEMBL2203825 | 0.84 | TSHR (0.44) | BCHEACHECA2CA1RORC | |
| SCHEMBL2202511 | 0.84 | CA2 (0.41) | BCHEACHECA2CA1RORC | |
| SCHEMBL12426479 | 0.82 | CXCR4 (0.41) | LTA4HBCHEACHEPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | LTA4H 645/4885BCHE 235/4885ACHE 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.